The advent of targeted therapy has revolutionized the field of oncology, offering a more personalized approach to cancer treatment. Unlike conventional chemotherapy, which indiscriminately targets rapidly dividing cells, targeted therapies aim to interfere with specific molecules necessary for tumor growth and progression.
Targeted therapies can be broadly classified into two categories: small molecules and monoclonal antibodies. Small molecules are low-weight compounds that can penetrate the cell membrane and interact with intracellular targets. Monoclonal antibodies, on the other hand, are large proteins that cannot cross the cell membrane and are designed to target extracellular or cell surface molecules.
Targeted therapies work by blocking the growth signals of cancer cells, interfering with angiogenesis, promoting apoptosis, or enhancing the immune response against cancer cells. They have the advantage of being more selective, hence causing fewer side effects than traditional chemotherapy.
Despite the promising results of targeted therapies, challenges remain. These include the development of resistance, the high cost of these therapies, and the difficulty in identifying appropriate molecular targets. However, ongoing research and technological advancements promise to overcome these obstacles and broaden the application of targeted therapies in cancer treatment.
Targeted therapy represents a significant advancement in modern oncology, offering a more tailored approach to cancer treatment. By specifically targeting cancer cells, these therapies minimize damage to healthy cells and reduce side effects. Despite existing challenges, the potential of targeted therapies is vast and continues to be explored in ongoing research. As healthcare professionals, staying abreast of these developments is crucial to provide the best care for our patients.
1.
Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?
2.
The need for more Latinx participants in Alzheimer's trials is urgent.
3.
Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.
4.
Study identifies new approach to protect the brain during radiation therapy
5.
Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD
1.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
2.
Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth
3.
The Genetics of Bernard Soulier Syndrome: What We Know so Far
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
Unlocking The Power Of Cangrelor To Treat Heart Disease
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
2.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
3.
Navigating the Complexities of Ph Negative ALL - Part XV
4.
Lung Cancer: Risk Factors and Prevention
5.
Thromboprophylaxis In Medical Settings
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation